247 related articles for article (PubMed ID: 14607912)
1. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
[TBL] [Abstract][Full Text] [Related]
2. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
3. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Takahashi N; Udagawa N; Suda T
Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Mochizuki S; Tomoyasu A; Yano K; Goto M; Murakami A; Tsuda E; Morinaga T; Higashio K; Udagawa N; Takahashi N; Suda T
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3597-602. PubMed ID: 9520411
[TBL] [Abstract][Full Text] [Related]
5. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.
Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T
J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146
[TBL] [Abstract][Full Text] [Related]
6. A novel molecular mechanism modulating osteoclast differentiation and function.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
[TBL] [Abstract][Full Text] [Related]
7. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.
Abu-Amer Y
J Clin Invest; 2001 Jun; 107(11):1375-85. PubMed ID: 11390419
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey DL; Timms E; Tan HL; Kelley MJ; Dunstan CR; Burgess T; Elliott R; Colombero A; Elliott G; Scully S; Hsu H; Sullivan J; Hawkins N; Davy E; Capparelli C; Eli A; Qian YX; Kaufman S; Sarosi I; Shalhoub V; Senaldi G; Guo J; Delaney J; Boyle WJ
Cell; 1998 Apr; 93(2):165-76. PubMed ID: 9568710
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
Hsu H; Lacey DL; Dunstan CR; Solovyev I; Colombero A; Timms E; Tan HL; Elliott G; Kelley MJ; Sarosi I; Wang L; Xia XZ; Elliott R; Chiu L; Black T; Scully S; Capparelli C; Morony S; Shimamoto G; Bass MB; Boyle WJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3540-5. PubMed ID: 10097072
[TBL] [Abstract][Full Text] [Related]
10. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.
Tsukii K; Shima N; Mochizuki S; Yamaguchi K; Kinosaki M; Yano K; Shibata O; Udagawa N; Yasuda H; Suda T; Higashio K
Biochem Biophys Res Commun; 1998 May; 246(2):337-41. PubMed ID: 9610359
[TBL] [Abstract][Full Text] [Related]
11. Bone remodelling: a signalling system for osteoclast regulation.
Filvaroff E; Derynck R
Curr Biol; 1998 Sep; 8(19):R679-82. PubMed ID: 9768352
[TBL] [Abstract][Full Text] [Related]
12. Malignant melanoma and bone resorption.
Lau YS; Sabokbar A; Giele H; Cerundolo V; Hofstetter W; Athanasou NA
Br J Cancer; 2006 May; 94(10):1496-503. PubMed ID: 16641914
[TBL] [Abstract][Full Text] [Related]
13. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.
Wang MW; Wei S; Faccio R; Takeshita S; Tebas P; Powderly WG; Teitelbaum SL; Ross FP
J Clin Invest; 2004 Jul; 114(2):206-13. PubMed ID: 15254587
[TBL] [Abstract][Full Text] [Related]
14. CD9 molecule expressed on stromal cells is involved in osteoclastogenesis.
Tanio Y; Yamazaki H; Kunisada T; Miyake K; Hayashi SI
Exp Hematol; 1999 May; 27(5):853-9. PubMed ID: 10340401
[TBL] [Abstract][Full Text] [Related]
15. The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats.
Benis KA; Schneider GB
Blood; 1996 Oct; 88(8):2898-905. PubMed ID: 8874186
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane inhibits osteoclastogenesis by inhibiting nuclear factor-kappaB.
Kim SJ; Kang SY; Shin HH; Choi HS
Mol Cells; 2005 Dec; 20(3):364-70. PubMed ID: 16404151
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.
Hofbauer LC; Heufelder AE
Eur J Endocrinol; 1998 Aug; 139(2):152-4. PubMed ID: 9724069
[No Abstract] [Full Text] [Related]
18. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.
Cenci S; Weitzmann MN; Roggia C; Namba N; Novack D; Woodring J; Pacifici R
J Clin Invest; 2000 Nov; 106(10):1229-37. PubMed ID: 11086024
[TBL] [Abstract][Full Text] [Related]
19. The Cytoplasmic Dynein Associated Protein NDE1 Regulates Osteoclastogenesis by Modulating M-CSF and RANKL Signaling Pathways.
Das BK; Gogoi J; Kannan A; Gao L; Xing W; Mohan S; Zhao H
Cells; 2021 Dec; 11(1):. PubMed ID: 35011575
[TBL] [Abstract][Full Text] [Related]
20. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.
Roato I; Porta F; Mussa A; D'Amico L; Fiore L; Garelli D; Spada M; Ferracini R
PLoS One; 2010 Nov; 5(11):e14167. PubMed ID: 21152388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
